Localized Carcinoma, Prostate Cancer
Conditions
Brief summary
The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based on a combination of elevated PSA levels (e.g. \>2.5 ng/ml) and/or pathological digital rectal examination and/or MRI-findings.
Interventions
DIAGNOSTIC_TESTStockholm3
Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
Sponsors
Department of Urology, University Hospital Freiburg, Freiburg, Germany
Department of Urology, Kantonsspital Graubünden, Chur, Switzerland
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 99 Years
Inclusion criteria
* Planned prostate biopsy due to suspicion of prostate cancer (usually due to a combination of elevated PSA levels \[e.g. \>2.5 ng/ml\] and/or pathological digital rectal examination and/or MRI-findings) * Written informed consent by the participant
Exclusion criteria
* Severe anemia (Hb \<60g/l) * Previously already established diagnosis of prostate cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cancer detection | 2020-2022 | Correlation between Stockholm3 and histological diagnosis of prostate cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease state | 2020-2022 | Correlation between Stockholm3 and clinical disease stage |
Countries
Switzerland
Outcome results
None listed